Shuttle Pharmaceuticals Granted U.S. Patent #12077515 For Selective Histone Deacetylase Inhibitors To Treat Human Diseases
Portfolio Pulse from Benzinga Newsdesk
Shuttle Pharmaceuticals has been granted a U.S. patent for its selective histone deacetylase inhibitors, which are used to treat human diseases. This patent could enhance the company's intellectual property portfolio and potentially lead to new treatment options.
September 03, 2024 | 7:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Shuttle Pharmaceuticals has received a U.S. patent for its selective histone deacetylase inhibitors, which could strengthen its intellectual property and open new avenues for treatment development.
The granting of a U.S. patent is a significant milestone for Shuttle Pharmaceuticals, as it strengthens their intellectual property portfolio. This can lead to increased investor confidence and potential partnerships or collaborations, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100